SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $640,000 | -25.9% | 25,334 | -27.5% | 0.00% | 0.0% |
| Q3 2016 | $864,000 | +104.7% | 34,951 | +68.6% | 0.00% | – |
| Q2 2016 | $422,000 | +75.1% | 20,728 | +31.0% | 0.00% | – |
| Q1 2016 | $241,000 | +20.5% | 15,822 | +6.3% | 0.00% | – |
| Q4 2015 | $200,000 | -35.3% | 14,882 | -32.3% | 0.00% | – |
| Q3 2015 | $309,000 | -16.0% | 21,994 | +1.5% | 0.00% | – |
| Q2 2015 | $368,000 | +89.7% | 21,664 | +35.3% | 0.00% | – |
| Q1 2015 | $194,000 | +70.2% | 16,012 | +16.5% | 0.00% | – |
| Q4 2014 | $114,000 | +9.6% | 13,739 | +14.4% | 0.00% | – |
| Q3 2014 | $104,000 | -23.0% | 12,010 | -2.8% | 0.00% | – |
| Q2 2014 | $135,000 | +42.1% | 12,362 | +16.2% | 0.00% | – |
| Q1 2014 | $95,000 | +58.3% | 10,643 | +34.6% | 0.00% | – |
| Q4 2013 | $60,000 | +17.6% | 7,909 | +13.5% | 0.00% | – |
| Q3 2013 | $51,000 | +18.6% | 6,971 | +3.4% | 0.00% | – |
| Q2 2013 | $43,000 | – | 6,743 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |